Developing breakthrough oncology drug candidates
Our research & development
Read more
Don't miss any news, subscribe on our press releases.
Subscribe to our newsletter
We are driven by make a difference for those affected by cancer
Sprint Bioscience is a pharmaceutical company focused on developing innovative drug candidates that can contribute to new treatments for cancer. The great need for new treatments for difficult-to-treat cancer brings great commercial potential.
Using a fragment-based drug development approach, we develop drug programs in a time- and resource-efficient manner that are out-licensed to global pharmaceutical companies during the preclinical phase.
Press releases
Show all
Read our articles
Show all
Sprint Biosciences upcoming activities
Sprint Bioscience summarizes below its upcoming meetings with potential partners and investors. International partnering and investor conferences: September 18-19: Nordic Life Science Days, Malmö, Sweden October 8-9: LSX Nordic Congress, Copenhagen, Denmark November 4-6: BIO-Europe Stockholm, Sweden November 20-21: BioStock Life Science Summit
Read more
20 Aug 2024
Interview with Sprint Biosciences CEO on participation at Bio International 2024
The Bio International Convention partnering conference was held June 3-6 in San Diego, California. Sprint Biosciences CEO Johan Emilsson was there. What general impressions do you take home from the conference? "It is almost always high pressure at this conference. It is one of the largest and most prestigious partnering conferences in biotechnology and drug development with...
Read more
20 Jun 2024
Sprint Biosciences upcoming activities
Sprint Bioscience summarizes below its upcoming meetings with potential partners and investors. International partnering and investor conferences: March 18-20, 2024: BIO-Europe Spring, Barcelona, Spain April 29-30, 2024: LSX World Congress, London, England June 3-6, 2024: BIO International Convention, San Diego, USA
Read more
1 Mar 2024
Redeye interviews Sprint Bioscience CEO Johan Emilsson
Following the press release on December 15 regarding the Vps34 program, Redeye's analysts ask some questions to Sprint Biosciences CEO, Johan Emilsson. The interview is also available at Redeye. Why is Deciphera returning the program? According to the agreement, they have the right to return the program without specifying any reason and they have chosen not to go public with the reason. May this...
Read more
18 Dec 2023
Happening in the future
Show all